Skip to main content
Erschienen in: hautnah dermatologie 5/2018

14.09.2018 | Metastasen | Zertifizierte Fortbildung

Neuroendokrines Karzinom der Haut

Merkelzellkarzinom: selten, aber aggressiv

verfasst von: Prof. Dr. Wiebke K. Ludwig-Peitsch, Dr. Elvira Ruppel, Dr. Axel Zahn

Erschienen in: hautnah dermatologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Merkelzellkarzinom ist ein seltenes, aggressiv verlaufendes neuroendokrines Karzinom der Haut. In der Ära der Chemotherapie war die Prognose bei Fernmetastasierung nahezu infaust — mit Einführung der Immuncheckpointinhibitoren wurde das Spektrum der Therapieoptionen wesentlich erweitert.
Literatur
1.
Zurück zum Zitat Fitzgerald TL et al. Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States. Am Surg 2015; 81: 802–6PubMed Fitzgerald TL et al. Dramatic Increase in the Incidence and Mortality from Merkel Cell Carcinoma in the United States. Am Surg 2015; 81: 802–6PubMed
2.
Zurück zum Zitat Schadendorf D et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71: 53–69CrossRefPubMed Schadendorf D et al. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer 2017; 71: 53–69CrossRefPubMed
3.
Zurück zum Zitat Coggshall K et al. Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging. J Am Acad Dermatol 2018; 78: 433–42CrossRefPubMed Coggshall K et al. Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging. J Am Acad Dermatol 2018; 78: 433–42CrossRefPubMed
5.
Zurück zum Zitat Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012; 7: 123–44CrossRefPubMed Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 2012; 7: 123–44CrossRefPubMed
6.
Zurück zum Zitat Becker JC et al. S2k Kurzleitlinie — MCC. J Dtsch Dermatol Ges 2013; 11 (Suppl 3): 31–8CrossRef Becker JC et al. S2k Kurzleitlinie — MCC. J Dtsch Dermatol Ges 2013; 11 (Suppl 3): 31–8CrossRef
7.
Zurück zum Zitat Harms KL et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 2016; 23: 3564–71CrossRefPubMedPubMedCentral Harms KL et al. Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. Ann Surg Oncol 2016; 23: 3564–71CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Samimi M et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol 2016; 174: 813–22CrossRefPubMed Samimi M et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol 2016; 174: 813–22CrossRefPubMed
9.
Zurück zum Zitat Bhatia S et al. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases from the National Cancer Data Base. J Natl Cancer Inst 2016; 108 Bhatia S et al. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases from the National Cancer Data Base. J Natl Cancer Inst 2016; 108
10.
Zurück zum Zitat Tello TL et al. Merkel cell carcinoma: An update and review: Current and future therapy. J Am Acad Dermatol 2018; 78: 445–54CrossRefPubMed Tello TL et al. Merkel cell carcinoma: An update and review: Current and future therapy. J Am Acad Dermatol 2018; 78: 445–54CrossRefPubMed
11.
Zurück zum Zitat Kaufman HL et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374–85CrossRefPubMedPubMedCentral Kaufman HL et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17: 1374–85CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kaufman HL et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6: 7CrossRefPubMedPubMedCentral Kaufman HL et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6: 7CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat D’Angelo SP et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol 2018; https://doi.org/10.1001/jamaoncol.2018.0077CrossRefPubMedPubMedCentral D’Angelo SP et al. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol 2018; https://​doi.​org/​10.​1001/​jamaoncol.​2018.​0077CrossRefPubMedPubMedCentral
Metadaten
Titel
Neuroendokrines Karzinom der Haut
Merkelzellkarzinom: selten, aber aggressiv
verfasst von
Prof. Dr. Wiebke K. Ludwig-Peitsch
Dr. Elvira Ruppel
Dr. Axel Zahn
Publikationsdatum
14.09.2018
Verlag
Springer Medizin
Erschienen in
hautnah dermatologie / Ausgabe 5/2018
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI
https://doi.org/10.1007/s15012-018-2610-3

Weitere Artikel der Ausgabe 5/2018

hautnah dermatologie 5/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.